throbber
2l9fZ)16
`
`Xeljanz — FieroePlarmdl:1aketing
`
`FieroePharmaMarketin
`
`v
`
`< Select another site I Advems.
`
`
`
`EMAIL ADDRESS
`
`[SIGN ME UP
`
`NEWS TOPICS ANALYSIS FEATURES JOBS
`
`FOLLOWUS @
`
`JOIN 24,000+ INSIDERS
`SIGN UP FOR OUR
`NEWSLETTER
`FiercePharmaMarkefing is the leading source of
`pharrna marketing news with a special focus on
`consumer advertising. DTC trends, new ting
`launches, and more. Join your fellow pharrna
`marketing executives who get
`FieIcePharmaMarkell’ng via email. Sign up today!
`
`EMAIL ADDRESS
`
`SIGN ME UP
`
`Tracking Trends in
`Consumer Health Dose
`Formulation
`
`$153
`
`DOWNLOAD Ton
`
`POPULAR STORIES
`
`MOST READ MOST SHARED
`
`Va|eant_ Astraleneca played the Super Bowl ad
`game, but did they win?
`'Safe' social network Linkedln emerges as popular
`marketing tool for pharrna
`Pfizer keeps pushing on ealy hit lbrance as
`Navartis, Lilly rivals near market
`GSK's slow-off-the-blocks Anoro gets a leg up from
`lncmse sidekick
`
`Docs take aim at Novartis' horrifying‘ Entresto ad
`
`THE LIBRARY: WEBINAR
`Special Considerations for Managing Immuno-
`oncology Studies - A New Paradigm
`|MARCH9|11AMETIBAMPT|
`PRESENTED av: MEDPACE
`
`Fierce
`Phar'maMarketing
`
`Xeljanz
`The top 10 most-advertised prescription drug brands
`
`SHARE
`
`Email
`
`Total: $160.7 million
`
`Pfizer's ($PFE) rheumatoid arthritis drug Xejanz has been
`
`
`
`gaining steam since its launch in 2012, both in ad spending 3
`and in sales. Pfizer spent more than $160 million last year
`.
`to advertise Xejanz, up 69% from $94.9 million in 2013.
`
`W ‘
`Sales leaps were even higher, with Pfizer recording a
`‘
`V
`revenue increase of 170% year over year to $308 million for O V
`the drug. Still, Xejanz has been another slow—tdgrow drug
`xdlanz.
`for Pfizer which had once pegged peak sales expectations
`(mfacmnib)
`at $3 billion annually.
`
`E] Tablets
`
`II any
`
`p
`
`,
`E
`
`Xeljanz was accepted ear1ier this year for FDA review for
`the treatment of adult psoriasis, an indication that could
`boost sales, although it's entering an already crowded fieldL
`where blockbuster Humira is well entrenched.
`
`For more:
`
`Psoriasis data wars heat up at AAD with Novartis, Boehringer studies
`Psoriasis study does little to help Pfizer with Xeljmz
`Pfizer's potential stars Eliquis, Xe janz see sluggish sales
`
`Special Report: The top 10 most-advertised prescription drug brands
`Cialis
`Latuda
`
`
`
`Lyrica
`
`Eliquis
`
`Viagra
`
`Humira
`
`Xeljanz
`
`Celebrex
`
`Ability
`
`Chantix
`
`am ’
`um
`
`
`mp‘!/www.fiercemamanaketingo<xnIspeci.=l—repor1sItq>1(}most—adver isedprescrimiorvd'ug»braid-:rxeljaiz
`
`1/3
`
`Page 1 of 2
`
`SENJU EXHIBIT 2299
`
`LUPIN v. SENJU
`
`IPR2015—0l100
`
`

`
`292016
`
`Xeljaiz - FieroePlamdwaketing
`
`‘
`
`lmmmoonoologywebinarweareinanew
`eraforresearclirtgcalcertieatmerlts. Join
`Methane medical and operations experts as
`they dscuss the unique considerations lot
`mmaghg immulo-oncology studes as well as
`insiglts into best practices. Register now!
`MORE ITEMS
`
`LATEST COMMENTARY
`
`Pharma marketers steer through changing tides
`What caught our readers‘ fancy this year? Here's
`your top 10 FiercePharmaMarketing capsule
`Merck KGaA exits ‘sea of s:«n'neness' with futuristic
`rebrand
`
`For sale: Orange paint. It might just become your
`brand's signature
`FiercePharmaMarketing will now publish every
`Monday and Wednesday
`
`EVENTS
`
`Brand New Modular Bioprocessing Facility
`From Novartis
`Febnary 17, 2016 — Charleston, SC
`MORE EVENTS
`
`PATIENT sumnr
`PlillIiRAMS:TllE|ll
`USE AND VMUE
`
`TAKE SURVEY ~
`
`ta‘
`=2
`I :
`"lF5"lVfV
`mpg“ mg
`mm mm!
`
`T
`‘
`
`FEATURED JOBS
`
`
`A publication of
`The Fieroeflukets Network:
`FIEPCEMHPRBT-S
`Telecorn
`_
`V
`,
`Fiercecable
`F'9'¢9Pha'"'-‘iM3'*9""9 '5
`FieroeDeveloper
`the bail-9 source o{
`Fieroewireless Europe
`-
`.
`riercevlnrelessrech
`'"a'ke""9 "e''5 ‘'’'u'
`Fieroeonlinelfideo
`3 59993 focus 0"
`FierceTelecom
`ierce st or
`lF‘ieroel:irea:ss
`
`Life Sciences
`Fiercesiotecnnesearcn
`Fiemeaiotecn
`Fieroefliotechfi
`FierceCRO
`Fierceorugnelivery
`Fiercelledicaloevices
`ierce
`arm sin
`FiercePhannaManufacturing
`FiercePhamaMar1reting
`FrerceAmmalHealth
`Fiemevaocines
`
`Enterprise IT
`Fiereeaigoata
`FieroeCl0
`Fieroecontentflanagement
`FierceDev0ps
`FieroeEnIerpriseComrnunicatio
`FierceI'l’Security
`
`Fieroellobilefl
`Energy
`Fiercefinergy
`Frercewater
`SrnartGridNews
`
`Finance
`
`cc"
`
`Healthcue
`FierceEMR
`Fierceflealthcare
`Fieroeflealthfinance
`Fierceflealthfl’
`FieroeHealthPayer
`FierceHealthPayerAntiFraud
`ierce acticc anagernent
`:ieroe-rrobileflaalthcare
`Hospital Impact
`
`Frerceeovemment
`Govemment
`FiereeGovernInentlT
`Fierceflomelandsecurity
`
`'l:ieroeMi<t>;isleGovemment
`F‘rerceGovHealthl'l'
`
`consglneg ¢dVeni5ing_
`DTC Hams‘ new dmg
`launches, and more. Join
`_
`.
`your fellow phanna
`mafkdmg execmwes Mn
`get FiercePharmaMarketing
`
`Via ema-I fa. me‘, must
`'"‘°W "9"’5-
`
`Click here to get your free
`ema'l briefing today!
`
`Marketing 5. Retail
`Frercelllobilemarketer
`FieroeCMQ
`FierceRetaiI
`FieroeRetaillT
`
`FieroeMobileRetail
`
`Home I Subscr be I Manage Newsletter Subscriptions lAdvertise I Contact I Mobile Apps I RSS I Privacy I Editorsl List in Marketplace
`0 2016 Fien:eMarliels, a division of Questex. LLC. All rigits reserved.
`
`mp1Mww.fiacemamanaketirIgcanIspecid—rerxxtsI|up1(}most—aiver isedprescrinion—d11gbr:-ndsrxeljalz
`
`23
`
`Page 2 of 2

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket